RRRolf Rau

Rolf Rau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rolf Rau has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 28 April 2014
      • Vol. 32  (3) , 395-400

    The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline.

    by D Krause, B Gabriel, G Herborn, J Braun, R Rau

    Methotrexate (MTX) is the anchor drug in the treatment of patients with rheumatoid arthritis (RA). MTX shows effects on disease activity and mortality. However, it is unclear whether the effect of MTX on mortality depends on its effect on disease activity. In a post-hoc analysis we analysed the data of our cohort established in Ratingen, Germany, and included all patients starting treatment with MTX (n=271) between 1980 and 1987. One year after baseline (BL), response to MTX treatment was assessed using a modified ACR 20 response. Follow-up data of 250 patients were available after 10 and 18 years. After 1 year, there were 66% responders and 20% non-responders; only 14% had discontinued MTX treatment due to side effects or lack of efficacy. Most patients continued MTX treatment irrespective of efficacy. Ten years after BL, 61% of the patients were still treated with MTX. After 18 years, the responder-group showed a standardised mortality ratio of 1.6 compared to 3.2 for the group of non-responders. However, when adjusting for age, gender, response to MTX treatment one year after BL, number of swollen joints and comorbidities after 10 years an independent association of continued MTX treatment with lower mortality was found for the period 10 to 18 years after BL (hazard ratio (HR): 0.63, 95% confidence interval: 0.43-0.92, p=0.015). In this cohort, the mortality lowering effect of continued MTX use was partly independent of its effect on disease activity. This finding may affect treatment decisions concerning RA patients with insufficient response to MTX.


    • 21 October 2011
      • Vol. 29, S68-72

    A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial.

    by S Wassenberg, R Rau, H Zeidler, Low-Dose Prednisolone Trail Group

    Glucocorticoids (GC) have been used to treat rheumatoid arthritis (RA) for more than 60 years. Despite this very long experience, there remains considerable debate concerning the adequate dosing and timing of these medications, primarily because of frequent and sometimes serious side effects, particularly in high doses. GCs are documented to provide immediate symptomatic relief and to decrease signs of inflammation in active disease. At the time when the Low-Dose Prednisolone Trial (LDPT) was designed, no clear evidence was available concerning whether low doses of GCs given over a long period add to slowing of structural damage in RA. The trial was therefore designed to test the hypothesis that even a low dose of prednisolone that was thought to cause no or only very limited harm could slow radiographic progression. The trial therefore included patients with active early RA (disease duration less than two years) who received either prednisolone 5 mg/day or placebo on concomitant DMARD therapy with parenteral gold or methotrexate for two years. Radiographs of hands and feet were taken at baseline, and at 6, 12 and 24 months. Structural damage was assessed using change in the Ratingen score (0-190 scale) as the primary outcome, and change in the Sharp/van der Heijde score (0-448 scale) for additional information concerning the same radiographs. Of 192 patients in the study, 166 were available for intention to treat analysis (ITT), and 76 completed the study per protocol (PP). Progression of the Ratingen score was significantly less at all consecutive time points in the prednisolone group compared to the control group, with the greatest difference after 6 months. At 24 months the increase in score in the prednisolone group was 1.2 ± 3.5, (95% CI 0.4-2.1) and in the placebo group 4.3 ± 6.8 (95% CI 2.7-5.9) (p=0.006, ITT-analysis). This was confirmed by the results of the Sharp/van der Heijde erosion and total score with an increase of the total score of 5.3 ± 10.7 units in the prednisolone compared to 11.4 ± 19.1 in the placebo group (p=0.022) at 24 months. The LDPT trial therefore confirmed that a very low daily dose of 5 mg prednisolone given over two years in combination with background DMARD therapy substantially decreases radiographically detectable damage in patients with early RA.


  • Evidenzbasierte Empfehlungen einer nationalen Expertenrunde zum Einsatz von Methotrexat bei entzündlich-rheumatischen Erkrankungen

    by I. H. Tarner, B. Manger, M. Fleck, E. Gromnica-Ihle, G. Keyßer, L. Köhler, I. Kötter, K. Krüger, J. Kuipers, H.-M. Lorenz, et al.

    Hintergrund: Methotrexat (MTX) ist eines der am häufigsten eingesetzten Basistherapeutika bei rheumatischen Erkrankungen. In der klinischen Praxis und zahlreichen Therapiestudien ist MTX der Goldstandard für die Behandlung der rheumatoiden Arthritis. Dennoch hat eine Umfrage im Rahmen der internationalen 3e-Initiative (Evidence, Experts, Exchange) unter nationalen und internationalen Experten 10 unzureichend geklärte Fragen zur klinischen Anwendung von MTX erbracht. In diesem Projekt sollten daher evidenzbasierte Empfehlungen für die Anwendung von MTX erarbeitet werden. Die nationalen Empfehlungen der deutschen Expertengruppe werden hier vorgestellt. Material und Methoden: Zwischen Januar und April 2007 wurden von Experten aus 17 Ländern 10 Fragen zur Anwendung von MTX formuliert. Zur Beantwortung der Fragen erfolgte bis Oktober 2007 durch „Multinational Fellows” eine systematische Literaturrecherche gemäß der aktualisierten Empfehlungen des Cochrane Instituts, deren Ergebnisse den nationalen Expertenrunden zur Verfügung gestellt wurden. Aus insgesamt 17 000 gefundenen Artikeln konnten nur 304 Arbeiten identifiziert werden, die zur Beantwortung der 10 Fragestellungen geeignet waren. Diese Arbeiten waren die Grundlage für die Erarbeitung der Expertenempfehlungen mittels eines Delphi-Verfahrens. Ergebnisse: Die gestellten Fragen zu MTX wurden in die Themengruppen (A) Therapiestrategien, (B) Therapiesicherheit – Überwachung und Prävention und (C) Therapiesicherheit – Komplikationen eingeteilt. Auf den nationalen Treffen wurden unter der Leitung des wissenschaftlichen Komitees von 68 deutschen Rheumatologen interaktiv 10 Empfehlungen mit einem mittleren Grad der Annahme von 90% erarbeitet. Schlussfolgerungen: Die 3e-Initiative hat aufgezeigt, dass hinsichtlich des praktischen Einsatzes von MTX bei rheumatischen Erkrankungen trotz langjähriger Erfahrung wichtige Fragen unzureichend geklärt sind. Die hier referierten evidenzbasierten Empfehlungen zu Anwendung, Therapieüberwachung und Management therapeutischer Komplikationen stellen einen nationalen Konsens erfahrener Experten dar, haben für die rheumatologische Praxis hohe Bedeutung und können als Basis zur Erarbeitung von zukünftigen Therapierichtlinien dienen. Background: Methotrexate (MTX) is one of the most frequently used disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatic diseases. In clinical practice as well as in clinical trials, MTX is the gold standard for the treatment of rheumatoid arthritis. Nevertheless, a survey by the international 3e-initiative (Evidence, Experts, Exchange) among national and international experts identified 10 questions regarding the clinical use of MTX that had not yet been clarified. Therefore, it was the goal of this project to develop evidence-based recommendations on the use of MTX. Materials and Methods: Between January and April 2007, experts from 17 countries agreed on 10 questions regarding the use of MTX. For answering these questions, “multinational fellows” performed a systematic literature research (SLR) up to October 2007. The SLR was completed according to the current recommendations of the Cochrane Collaboration and its results were presented to national groups of experts. Out of 17 000 articles retrieved by the SLR, only 304 articles were found to be applicable for answering the 10 questions. Based on these articles, recommendations were developed using a Delphi procedure. Results: The 10 questions were divided into three topics: (A) therapeutic strategies, (B) treatment safety – monitoring and prevention and (C) treatment safety – complications. At the national meetings guided by the scientific committee, 68 German rheumatologists developed 10 recommendations in an interactive setting with a mean degree of acceptance of 90%. Conclusion: The 3e-initiative has demonstrated that, despite long-standing experience with MTX, several issues with regard to its use in rheumatic diseases are currently unclear. The evidence-based recommendations on the use and monitoring of MTX as well as the management of therapeutic complications reported in this article represent the national consensus of experienced experts in the field and are of high importance for daily practice in rheumatology and for the development of future therapeutic recommendations.


  • Open Access

    Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis

    by Désirée van der Heijde, Robert Landewé, Annelies Boonen, Steve Einstein, Gertraud Herborn, Rolf Rau, Siegfried Wassenberg, Barbara N Weissman, Carl S Winalski, John T Sharp

    The objective of the present study was to test the hypothesis that experts recognize repair of erosions and, if so, to determine which, if any, morphologic features permitted them to recognize the repair. We also tested whether scoring by a standard method detected repair. Seven experienced readers of radiographs in rheumatoid arthritis were presented with 64 sets of single joints-of-interest at two time points, randomized and blinded for the correct sequence. The readers assessed which joint was better, and recorded whether any of six specific features were seen. Two independent readers, experienced in scoring by the van der Heijde-modified Sharp method who were not on the expert panel, then scored the complete films that included the joint-of-interest. The panel agreed very well on which of two joints was better, and, even though they did not know the true sequence, the panel accurately assigned a sequence slightly better than chance alone (58%) but worse than their agreement on which image was 'better or worse' (78%). The readers therefore indirectly assigned repair by choosing the second film as the best. Putative repair features were seen in cases of both repair and progression, and were not discriminatory. Similar results were obtained when the experts were presented with the entire hand or foot containing the joint-of-interest. In the third repair exercise, two independent readers who scored whole hands and feet using a standard method found a mean negative score in 22/60 joints-of-interest. All 22 joints were also scored as repair by the panel. Repair was detected reliably by a majority of the panel on viewing paired images based on a better/worse decision and assigning sequence in a set of images that were blinded for sequence by an independent project manager. In this test set of images, repair was manifested by a reduction in the size of erosion in many cases. Size was one feature that aided the experts to detect repair but cannot be the only one; the experts had to find other features to determine whether a smaller erosion was the first in a sequence of radiographs in a patient with progressive damage or was the second film in a patient exhibiting repair. The change in size of erosion was also picked up by independent readers applying the van der Heijde-modified Sharp scoring method and was reflected in their scores.


  • Open Access

    Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

    by Joachim Listing, Anja Strangfeld, Rolf Rau, Jörn Kekow, Erika Gromnica-Ihle, Thilo Klopsch, Winfried Demary, Gerd-Rüdiger Burmester, Angela Zink

    We investigated the frequency of remission according to the disease activity score (DAS28) definition, modified American Rheumatology Association (ARA) criteria, and the frequency of an achievement of a functional status above defined thresholds ('functional remission', 'physical independence') in rheumatoid arthritis (RA) patients treated with either biologics or conventional DMARDs. We used the data of a prospective cohort study, the German biologics register RABBIT (German acronym for Rheumatoid Arthritis – Observation of Biologic Therapy) to investigate the outcomes in RA patients with two or more DMARD failures who received new treatment with biologics (BIOL; n = 818) or a conventional DMARD (n = 265). Logistic regression analysis was applied to adjust for differences in baseline risks. Taking risk indicators such as previous DMARD failures or baseline clinical status into account, we found that biologics doubled the chance of remission compared to conventional DMARD therapies (DAS28 remission, adjusted odds ratio (OR) 1.95 (95% confidenece interval (CI) 1.2–3.2)); ARA remission, OR 2.05 (95% CI 1.2–3.5)). High remission rates (DAS28 remission, 30.6%; ARA remission, 16.9%) were observed in BIOL patients with a moderate disease activity (DAS28, 3.2 to 5.1) at the start of treatment. These rates decreased to 8.5% in patients with DAS28 > 6. Sustained remission at 6 and 12 months was achieved in <10% of the patients. Severely disabled patients (≤50% of full function) receiving biologic therapies were significantly more likely to achieve a status indicating physical independence (≥67% of full function) than controls (OR 3.88 (95% CI 1.7–8.8)). 'Functional remission' (≥83% of full function) was more often achieved in BIOL than in controls (OR 2.18 (95% CI 1.04–4.6)). In conclusion, our study shows that biologics increase the chance to achieve clinical remission and a status of functional remission or at least physical independence. However, temporary or even sustained remission remain ambitious aims, which are achieved in a minority of patients only.


  • Bildgebende Verfahren in der Rheumatologie: Konventionelle Röntgendiagnostik bei der rheumatoiden Arthritis

    by R Rau, G Lingg, S Wassenberg, C Schorn, A Scherer, Kommission "bildgebende Verfahren" Der Deutschen Gesellschaft Für Rheumatologie


    • 24 November 2004
      • Vol. 22, S44-9

    Healing of erosive changes in rheumatoid arthritis.

    by R Rau, G Herborn, S Wassenberg

    This is an overview over the history and present state of knowledge of radiographic signs of erosion healing. The existence of healing or repair has been confirmed; different observers agree in the identification of healing; it may be identified without knowing the sequence of the films. As healing indicates that inflammation has discontinued for several months in an individual joint, it might represent a good additional outcome measure in RA clinical trials.


    • 24 November 2004
      • Vol. 22, S83-94

    Benefit and risk of methotrexate treatment in rheumatoid arthritis.

    by R Rau, G Herborn

    This is a literature review on the efficacy and toxicity of low dose weekly methotrexate treatment in rheumatoid arthritis. Personal recommendations on dosing and monitoring (of) the drug are given.


  • Have traditional DMARDs had their day?

    by Rolf Rau

    This review tries to answer the question of whether in the face of the recently introduced biologics conventional disease-modifying antirheumatic drugs (DMARDs) can still be recommended in the treatment of rheumatoid arthritis (RA). We start with an overview of the oldest conventional DMARD, injectable gold (Au), which was introduced in the treatment of RA in the 1920s. The effect of gold is directed at a number of different sites of the immune system. A significant improvement of clinical and biochemical disease activity parameters as well as an inhibition of X-ray progression has been shown in many studies. Head-to-head comparisons between gold and high-dose methotrexate (MTX) demonstrated no significant difference but some advantages for gold. Since trials comparing biologics with gold will never be performed, an indirect comparison was done by analyzing the results of trials with gold with those with biologics. Conclusions from such comparisons have to be drawn with caution especially since the methodology for performing trials has changed with time. We selected four trials with gold (two open, one placebo-controlled, and one comparison with MTX) and five trials with biologics (three placebo-controlled, one dose escalation study, and one comparison with MTX). In all these trials baseline data regarding swollen joint count (SJC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were roughly comparable and, with the exception of interleukin (IL)-1 RA, demonstrated a similar improvement of over 50% already after 6 months [with faster onset with tumor necrosis factor (TNF)-alpha blockade]. American College of Rheumatology (ACR) response data were not available for the older gold trials. European League Against Rheumatism (EULAR) response criteria could be calculated for the Au/MTX trial and were—for these compounds—only slightly inferior to the results with adalimumab. X-ray response is especially difficult to compare across studies. Although an inhibition with Au and MTX could be demonstrated, this occurred—similar to corticosteroid treatment—earlier and more pronounced with TNF-alpha blockers. We confirm the statement of Weinblatt that the most modern DMARDs do not appear to be much better than the oldest one indicating that conventional DMARDs are not outdated. Therefore, a sufficient trial of conventional DMARDs should precede the introduction of treatment with the very expensive biologics.


  • Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate

    by R Rau, S Simianer, Plcm van Riel, Lba van de Putte, K Krüger, M Schattenkirchner, Cf Allaart, Fc Breedveld, J Kempeni, K Beck, et al.

    Objective: This randomized, placebo‐controlled, double‐blind, Phase 1 study assessed the magnitude, onset, and duration of response with intravenous (i.v.) and subcutaneous (s.c.) adalimumab (Humira®, Abbott Laboratories) combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite previous MTX therapy. Methods: Fifty‐four patients were randomized to two injections of i.v. or s.c. adalimumab (1 mg/kg) or placebo while continuing on MTX (mean dose, 15.7 mg/week). Dosing intervals were determined by the European League Against Rheumatism (EULAR) response criteria, and were allowed to range from 1 to 3 months. Efficacy was mainly assessed using the EULAR response criteria and the American College of Rheumatology (ACR) response criteria. Results: Moderate EULAR response was achieved at least once within 29 days after the first injection in 83% and 61% of patients receiving i.v. and s.c. adalimumab respectively, compared with 44% for placebo [probability (p)≤0.05 for i.v. adalimumab versus placebo]. A 20% improvement in disease activity according to the ACR criteria (ACR20 response) was achieved by 72% and 67% of patients receiving i.v. and s.c. adalimumab respectively, compared with 28% for placebo (p≤0.01 and p≤0.05, respectively, versus placebo). By Day 15 after the first and second injections, statistically significant moderate EULAR and ACR20 response rates were achieved with either i.v. or s.c. adalimumab compared with placebo (p ≤ 0.05). The mean times to second injection for i.v. adalimumab, s.c. adalimumab, and placebo were 42.2 days (range: 27–84 days), 38.3 days (range: 26–85 days), and 28.4 days (range: 26–32 days), respectively (minimum time allowed by the protocol between the first and second injections was 4 weeks). Adalimumab in combination with MTX was well tolerated, with no patients being withdrawn because of adverse events. Conclusion: Either i.v. or s.c. adalimumab added to MTX significantly improved the signs and symptoms of RA compared with MTX alone. Subcutaneously administered adalimumab appeared to provide a response that was as great, as rapid, and as enduring as that with i.v. adalimumab.